Ruxolitinib, the first JAK/STAT inhibitor approved by the FDA, enhances the expression of angiogenic factors by inducing NK cell–mediated tumor progression, suggesting that combined targeting of JAK/STAT and VEGF signaling can improve therapeutic response [34]. The gene discussed is VEGFA; the disease is neoplasm.